Cardinal Health, Inc. vs Tata Motors Limited: Strategic Comparison

This in-depth comparison examines Cardinal Health, Inc. and Tata Motors Limited across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Cardinal Health, Inc. on its own, evaluating Tata Motors Limited, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Cardinal Health, Inc. and Tata Motors Limited is widest.

On the headline numbers, Cardinal Health, Inc. reports annual revenue of $254.2B against ~$9.7B for Tata Motors Limited, while their respective market capitalizations stand at $56.0B and $17.5B. Cardinal Health, Inc. is headquartered in United States and Tata Motors Limited in India, and those different home markets shape how each company competes.

Cardinal Health, Inc.: Cardinal Health, based in Ohio, is one of the three large US pharmaceutical distributors, along with McKesson and Cencora. It does not invent drugs or treat patients. It runs the regulated supply chain that moves medicines and medical devices from manufacturers to pharmacies and hospitals, so a prescription collected at a local pharmacy has often passed through its network.

Tata Motors Limited: Tata Motors' history is broader than its current legal perimeter. The brand story includes trucks, buses, passenger cars, the Nano, EVs and JLR, but the current listed Tata Motors Limited is the commercial-vehicles successor.

Cardinal Health, Inc. and Tata Motors Limited pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Cardinal Health, Inc. and Tata Motors Limited.

Cardinal Health, Inc. business model: The business model is large, high-volume logistics divided into two segments: Pharmaceutical and Medical. In the Pharma segment, they buy billions of dollars of drugs from manufacturers (like Pfizer) and distribute them daily to tens of thousands of pharmacies and hospitals, taking a tiny markup. In the Medical segment, they actually manufacture and distribute low-cost, high-volume medical supplies (like surgical gloves, gowns, and syringes), acting as the large central supply closet for the entire American hospital system.

Tata Motors Limited business model: Tata Motors -- following an October 2025 demerger that split the historic company in two -- now refers specifically to the commercial-vehicle business: trucks, buses, and other heavy vehicles sold mostly to the Indian domestic market, plus a proposed international expansion through the pending Iveco Group acquisition. The passenger-vehicle business, Tata's EV operations, and Jaguar Land Rover (JLR) -- the UK luxury-SUV maker Tata acquired from Ford for $2.3 billion in 2008 -- now sit in a separately listed entity, Tata Motors Passenger Vehicles Limited, led by CEO Shailesh Chandra. The current, post-demerger Tata Motors Limited reported FY2026 consolidated revenue of about INR83,855 crore (roughly $8.7 billion), not comparable to the pre-demerger consolidated figures that included JLR's much larger revenue base. Tata has grown its commercial-vehicle scale through acquisition, including Daewoo Commercial Vehicle (2004) for South Korean heavy-truck technology, and has a proposed acquisition of European truck maker Iveco Group pending regulatory approval as of the FY2026 results. The commercial-vehicle demerger reflects a broader trend among diversified Indian conglomerates toward focused, pure-play listed entities that institutional investors can value more precisely than a combined structure spanning trucks, passenger cars, and an UK luxury brand with very different growth and margin profiles. Tata Motors Limited's post-demerger scale, while smaller than the pre-split combined entity, gives it a cleaner comparison set against other pure-play commercial-vehicle makers globally, including the Iveco Group it now aims to acquire.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Cardinal Health, Inc. stack up against those of Tata Motors Limited.

Cardinal Health, Inc. competitive advantage: Cardinal Health's advantage is physical scale and regulatory standing. Moving regulated, temperature-sensitive drugs and biologics across the country overnight takes a network of specialized distribution centers and security procedures that cost billions of dollars and take decades to build. The barrier to entry is high, so drug distribution is concentrated among a few large companies.

Tata Motors Limited competitive advantage: Tata Motors' advantage is its scale in Indian commercial vehicles, deep dealer and service reach, Tata brand trust, engineering base and ability to bundle vehicles, spares, fleet tools and service.

Future prospects matter as much as current results. The growth strategies below explain how Cardinal Health, Inc. and Tata Motors Limited each plan to expand from here.

Cardinal Health, Inc. growth strategy: Cardinal Health's growth plan rests on three levers. First, specialty pharmaceuticals and physician practice platforms: it bought a 71% stake in GI Alliance for about $2.8 billion (announced November 2024) and funded The Specialty Alliance's roughly $1.9 billion acquisition of urology MSO Solaris Health (completed November 2025). Second, the Other segment: Nuclear and Precision Health Solutions (radiopharmaceuticals and theranostics), at-Home Solutions (expanded with ADSG in 2025, Strive Medical, and the announced AdaptHealth diabetes business), and OptiFreight Logistics, which together grew revenue 26% to $6.8 billion in fiscal 2026. Third, improving GMPD profitability through its Cardinal Health brand products and cost actions.

Tata Motors Limited growth strategy: Tata Motors is growing through next-generation trucks, buses, electric and alternative-fuel commercial vehicles, Fleet Edge, service parts, exports, operational discipline and the planned Iveco expansion.

A closer look at the financial trajectory of Cardinal Health, Inc. and Tata Motors Limited rounds out the comparison.

Cardinal Health, Inc.: Cardinal Health combines very large revenue with thin margins. Fiscal 2026 revenue was $254.2 billion, up 14% from $222.6 billion in fiscal 2025, driven by brand and specialty drug volume from existing customers. GAAP operating earnings were $2.6 billion, GAAP diluted EPS was $7.23, and net earnings attributable to Cardinal Health were about $1.7 billion. Non-GAAP diluted EPS rose 37% to $11.26 ($10.95 excluding the IEEPA tariff refund). Operating cash flow was $5.2 billion and adjusted free cash flow was $5.0 billion. The company repurchased $1.4 billion of stock in fiscal 2026 and the board added $5.0 billion to the buyback authorization in August 2026. Fourth-quarter fiscal 2026 revenue was $63.7 billion, up 6%.

Tata Motors Limited: The post-demerger Tata Motors Limited reported FY2026 (year to March 31, 2026) revenue from operations of ~$9.73B (INR83,855 Cr), up 44% from ~$6.75B (INR58,217 Cr), as wholesales rose 14% to about 428,000 units. The jump partly reflects the changed perimeter after the demerger, so it is not a clean like-for-like growth rate. Profit for the year fell 5.2% to ~$351M (INR3,030 Cr), weighed by one-time demerger costs (about $111M (INR960 Cr) in Q3) and new labour-code charges. Momentum carried into Q1 FY2027: revenue rose about 20% to ~$2.39B (INR20,576 Cr) and attributable profit rose 83% to ~$297M (INR2,560 Cr), helped by a one-time gain linked to Tata Capital, while commodity costs squeezed margins.